A collaboration agreement has been announced by Domain Therapeutics and Pfizer, which is aimed at assessing the impact of mutations on different signalling pathways engaged by GPCRs.
Collaborate
Under the terms of the agreement, Domain Therapeutics will use its bioSensAll technology to define signalling signatures for each of the wild-type and mutant receptors. Through probing the structure-function relationships of various amino acid substitutions in each GPCR, potential targets across a range of therapeutic indications can be validated. Pfizer will use the results of specific mutations on intracellular signalling to guide further investigations in disease-specific models.
“We are very pleased to have signed this collaboration with Pfizer for the profiling of mutant GPCRs using the bioSensAll platform. It is yet another example of the wide applications of the technology, from target validation through to drug discovery and development,” said Pascal Neuville, chief executive officer of Domain Therapeutics. “By building a better understanding of the signalling profile needed for efficacy, bioSensAll may reduce the attrition rate of early-stage drug development.”
Domain Therapeutics is a biopharmaceutical company based in Strasbourg, France, and is dedicated to the discovery and early development of small molecules targeting GPCRs.